Taranabant merck
Web1Merck & Co., Inc, Whitehouse Station, NJ; 2Currently at FDA, Rockville, MD; 3Cognigen Corporation, Buffalo, NY; 4Currently at Global Alliance for TB Drug Development, New York, NY • Taranabant is a cannabinoid-1 receptor (CB1R) inverse agonist, that was being developed by Merck and Co., Inc. as a potential treatment of obesity[1]. WebTaranabant (N- [ (1S,2S)-3- (4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- { [5- (trifluoromethyl)pyridin-2-yl]oxy}propanamide or MK-0364) is an orally active inverse agonist of the cannabinoid 1 (CB-1) receptor that was under development for the management of obesity.
Taranabant merck
Did you know?
WebOct 2, 2008 · Merck ( NYSE: MRK) has taken a step that many people have been expecting, and announced that they are no longer developing taranabant, their … WebMar 12, 2008 · Last month I spent some time expressing doubts about Merck’s new obesity drug candidate taranabant, a cannabinoid-1 ligand similar to Sanofi-Aventis’s failed …
WebRimonabant is a selective central cannaboid (CB1) receptor antagonist. It is an appetite suppressant in advanced development for obesity treatment. The rationale behind this drug is to reduce appetite by blocking cannaboid receptors in the hypothalamus. WebJul 1, 2008 · Taranabant was preclinically studied for its effect on obesity and, similar to rimonabant, proved to be effective at promoting weight loss. ... Targeting the Endocannabinoid CB1 Receptor to Treat...
http://fatnews.com/index.php/forums/viewthread/79/ WebMar 10, 2008 · NEW YORK (Reuters) - Merck & Co's MRK.N experimental obesity drug taranabant did not show impressive effectiveness in a late-stage trial and its side effects were worse than expected, an...
WebFeb 25, 2008 · And Vioxx, as I said here at the time, was not, in my opinion, necessarily a bad drug. It and the other COX-2 inhibitors have a real place in the pharmacopeia. The …
WebBased on the available data from the phase III clinical study program for taranabant, Merck & Co., Inc. determined in October 2008 that the overall profile of taranabant did not support further development of the drug for the treatment of obesity (). However, the present study provides important information about the safety and efficacy of ... allegra auroraWeb申请人 : Merck Sharp & Dohme Corp. 摘要 : Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. allegra augentropfenWebJun 22, 2009 · We compared the pharmacological properties of taranabant with another inverse agonist, rimonabant, and determined the preclinical safety margins of taranabant. In vitro studies demonstrated that taranabant is ∼10‐fold more potent than rimonabant at the CB 1 receptor, and taranabant is more selective based on off‐target in vitro screening ... allegra avvocatoWebMar 10, 2008 · Analysts estimated taranabant could have brought in as much as $1 billion in annual sales, according to Salares. Merck had hoped to file an application to sell the … allegra asthma treatmentWebFeb 25, 2008 · Merck has taken a step that many people have been expecting, and announced that they are no longer developingtaranabant, their cannabinoid antagonist (or is it an inverse agonist?) I'd expressed grave doubtsabout the drug earlier this year, which turned out to be well-founded. allegra baiocchiWebMerck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the … allegra azzoni dottoressaWebMerck & Co. was developing taranabant, an orally active, selective cannabinoid receptor CB1 inverse agonist for the treatment of obesity and as an aid for Taranabant ... Taranabant Alternative Names: MK-0364 Latest Information Update: 02 Oct 2024. Price : $50 * Buy Profile. Adis is an information provider. ... allegra azzoni